Barclays
SLDB icon

Barclays’s Solid Biosciences SLDB Stock Holding History

Barclays’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$424K Sell
58,877
-79,259
-57% -$509K ﹤0.01% 3283
2025
Q4 		$779K Sell
138,136
-20,966
-13% -$114K ﹤0.01% 3601
2025
Q3 		$982K Sell
159,102
-22,444
-12% -$131K ﹤0.01% 3376
2025
Q2 		$884K Buy
181,546
+120,855
+199% +$427K ﹤0.01% 3416
2025
Q1 		$225K Buy
60,691
+6,131
+11% +$26.3K ﹤0.01% 3982
2024
Q4 		$218K Sell
54,560
-8,296
-13% -$45.6K ﹤0.01% 4265
2024
Q3 		$438K Buy
62,856
+50,582
+412% +$410K ﹤0.01% 3859
2024
Q2 		$69.6K Buy
12,274
+7,857
+178% +$70.4K ﹤0.01% 4072
2024
Q1 		$58.8K Hold
4,417
– – ﹤0.01% 4581
2023
Q4 		$27.1K Hold
4,417
– – ﹤0.01% 4865
2023
Q3 		$11.1K Hold
4,417
– – ﹤0.01% 4283
2023
Q2 		$23.1K Hold
4,417
– – ﹤0.01% 4107
2023
Q1 		$20.9K Sell
4,417
-20
-0.5% -$120 ﹤0.01% 4650
2022
Q4 		$23.9K Sell
4,437
-1
-0% -$7 ﹤0.01% 4773
2022
Q3 		$31K Sell
4,438
-106
-2% -$1.07K ﹤0.01% 3930
2022
Q2 		$42K Sell
4,544
-645
-12% -$6.7K ﹤0.01% 4101
2022
Q1 		$93K Sell
5,189
-4,180
-45% -$73.8K ﹤0.01% 3820
2021
Q4 		$246K Buy
9,369
+1,645
+21% +$50.3K ﹤0.01% 3494
2021
Q3 		$277K Buy
7,724
+1,844
+31% +$78.3K ﹤0.01% 3457
2021
Q2 		$322K Sell
5,880
-39,047
-87% -$2.58M ﹤0.01% 3317
2021
Q1 		$3.73M Buy
44,927
+43,302
+2,665% +$4.79M ﹤0.01% 1763
2020
Q4 		$185K Sell
1,625
-153
-9% -$9.68K ﹤0.01% 3802
2020
Q3 		$54K Sell
1,778
-154
-8% -$5.9K ﹤0.01% 4561
2020
Q2 		$84K Buy
1,932
+1,496
+343% +$62.1K ﹤0.01% 4632
2020
Q1 		$15K Sell
436
-2,772
-86% -$137K ﹤0.01% 5726
2019
Q4 		$214K Buy
3,208
+2,556
+392% +$282K ﹤0.01% 4988
2019
Q3 		$101K Sell
652
-1,479
-69% -$167K ﹤0.01% 5471
2019
Q2 		$184K Sell
2,131
-26,440
-93% -$2.88M ﹤0.01% 5183
2019
Q1 		$3.94M Buy
28,571
+28,532
+73,159% +$7.15M ﹤0.01% 1864
2018
Q4 		$16K Sell
39
-396
-91% -$186K ﹤0.01% 6003
2018
Q3 		$308K Buy
435
+240
+123% +$151K ﹤0.01% 4668
2018
Q2 		$104K Buy
195
+70
+56% +$21.5K ﹤0.01% 5214
2018
Q1 		$14K Buy
+125
New +$42.2K ﹤0.01% 6562

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Barclays's SLDB Position: Q1 2026 in Review

Barclays reduced its Solid Biosciences (SLDB) stake by 57% in Q1 2026, selling an estimated $509K and leaving 58,877 shares worth $424K. The position accounts for ﹤0.01% of the portfolio, ranked #3283.

Barclays first reported a position in SLDB in Q1 2018 and has held it in 33 quarters since. The position peaked at $3.94M in Q1 2019. 150 funds tracked by Wall St. Rank hold SLDB as of Q1 2026.

  • Barclays held 58,877 shares of Solid Biosciences worth $424K as of Q1 2026.
  • Barclays sold 79,259 Solid Biosciences shares in Q1 2026, an estimated $509K.
  • Solid Biosciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3283 holding.
  • Barclays first reported a position in Solid Biosciences in Q1 2018 and has held it in 33 quarters since.
  • Barclays's Solid Biosciences position peaked at $3.94M in Q1 2019.
  • 150 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.